Financial Results Approval

The Board of Directors of Sai Parenterals Limited approved the unaudited financial results for the quarter ended June 30, 2026, during their meeting held on August 11, 2026, at the Registered Office of the Company. The meeting commenced at 11:00 AM and concluded at 5:00 PM.

Standalone Financial Results (Q1 FY27)

  • Total Income: ₹562.47 million
  • Revenue from Operations: ₹542.63 million
  • Other Income: ₹19.84 million
  • Total Expenses: ₹443.62 million
  • Profit Before Tax: ₹118.30 million
  • Tax Expense: ₹29.55 million
  • Profit After Tax: ₹88.75 million
  • Basic EPS: ₹2.01 (before and after exceptional items)
  • Paid-up Equity Share Capital: ₹220.90 million (Face Value ₹5 per share)

Consolidated Financial Results (Q1 FY27)

  • Total Income: ₹1,824.13 million
  • Revenue from Operations: ₹1,786.72 million
  • Other Income: ₹37.41 million
  • Total Expenses: ₹1,726.23 million
  • Profit Before Tax: ₹97.90 million
  • Tax Expense: ₹18.67 million
  • Profit After Tax: ₹79.23 million
  • Basic EPS: ₹1.79 (before and after exceptional items)
  • Paid-up Equity Share Capital: ₹220.90 million

Director Appointments and Reappointments

1. Re-appointment of Mr. Anil Kumar Karusala (DIN: 01866646) as Director of the Company, retiring by rotation

2. Re-appointment of Mr. Anil Kumar Karusala as Managing Director for 3 years effective January 1, 2027, subject to shareholder approval

3. Re-appointment of Mrs. Vijitha Gorrepati (DIN: 03492979) as Whole-time Director for 3 years effective January 1, 2027, subject to shareholder approval

4. Appointment of Mr. Kunal Kakumanu (DIN: 11281388) as Additional and Executive Director for 3 years effective August 11, 2026, subject to shareholder approval

Resignations

1. Resignation of Ms. Shivali Aggarwal as Company Secretary & Compliance Officer on or before October 12, 2026 (due to personal reasons)

2. Resignation of Mrs. Aruna Karusala (DIN: 01673731) as Non-Executive Director effective August 11, 2026 (due to personal reasons)

IPO Proceeds Utilization Change

The Board approved variation in objects and terms of utilization of IPO proceeds and extension of time period for utilization, subject to shareholder approval:

Acquisition of Saicriti Pharma Private Limited

  • Original purpose: Capacity expansion and upgradation of manufacturing facilities (₹838.34 million)
  • New purpose: Acquisition of 60% equity shares in Saicriti Pharma Private Limited
  • Cost of acquisition: ₹83.83 crore (investment)
  • Saicriti Pharma is developing a state-of-the-art critical care sterile injectable manufacturing facility at Gummadidala, Hyderabad
  • Total estimated cost of development: ₹2,149.60 million
  • Industry: Pharma Sector
  • Timeframe: Before October 30, 2026
  • No governmental approvals required

Acquisition of Prathyak Laboratories Private Limited

  • Original purpose: Establishment of research & development centre (₹180.23 million)
  • New purpose: Acquisition of 60% equity shares in Prathyak Laboratories Private Limited
  • Cost of acquisition: ₹15 crore
  • Prathyak has an established pharmaceutical R&D organization at Genome Valley, Hyderabad with product portfolio of 124 products development
  • Industry: Pharma Sector
  • Timeframe: Before October 30, 2026
  • No governmental approvals required
  • Financial history: FY2025-26 Total Income ₹0.61 lakh, FY2024-25 ₹7.46 lakh, FY2023-24 NIL

ESOP Scheme Ratification

1. Ratification of Sai Parenterals Limited Employee Stock Option Plan, 2025 (ESOP Scheme-2025), subject to shareholder approval

2. Ratification of extension of ESOP Scheme-2025 benefits to subsidiary companies, subject to shareholder approval

Subsidiary Matters

1. Incorporation of a new step-down subsidiary in the United States of America as a Wholly Owned Subsidiary of Sai Parenterals Pte. Ltd., Singapore

2. Material Related Party Transaction: Grant of loan to Sai Singapore Pte. Ltd. for downstream funding to Noumed Pharmaceuticals Pty Limited, Australia (step-down subsidiary), subject to shareholder approval

3. Material Related Party Transaction with Noumed Pharmaceuticals Pty Limited for sale of goods and/or services for FY2026-27, subject to shareholder approval

Corporate Governance Matters

1. Notice of Annual General Meeting scheduled for September 10, 2026, at 11:00 AM through Video Conferencing/Audio-Visual Means

2. Directors' Report, Management Discussion and Analysis Report, and Corporate Governance Report for FY2025-26 approved

3. Reconstitution of Board Committees effective August 11, 2026:

  • Nomination and Remuneration Committee: Dr. Seeta Ram Anjaneyulu Gorantla (Member), Kalidindi V Raju (Member)
  • Stakeholders Relationship Committee: Dr. Seeta Ram Anjaneyulu Gorantla (Chairman), Bhagyashri Dharmasa Zad (Member), Kalidindi V Raju (Member)

4. Reconstitution of POSH Committee:

  • Mrs. Vijitha Gorrepati (Presiding Officer)
  • Mr. Kunal Kakumanu (Member)
  • Mrs. Sujitha Ravoori (External Member)
  • Mrs. Jalaja (Member)

Auditor Review

R Kabra & Co. LLP conducted limited review of both standalone and consolidated financial results and issued unmodified conclusions. The consolidated results include five subsidiaries: Revat Laboratories Private Limited, SP Analytics Private Limited, Sai Parenterals Pte. Limited, Noumed Pharmaceuticals Pty Limited, and Noumed Pharmaceuticals Limited.

Subsidiary Financials (Q1 FY27)

  • Revat Laboratories Private Limited: Revenue ₹190.33 million, Profit ₹50.58 million
  • Sai Parenterals Pte. Limited: Revenue ₹167.21 million, Profit ₹10.52 million
  • Noumed Pharmaceuticals Pty Limited: Revenue ₹1,037.09 million, Loss ₹89.53 million
  • Noumed Pharmaceuticals Limited: Revenue ₹95.96 million, Profit ₹8.52 million
  • LSP Analytics Private Limited: Revenue ₹0, Loss ₹0.50 million